Coding variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are associated with late-onset Alzheimer's disease (AD). We demonstrate that amyloid plaque seeding is increased in the absence of functional Trem2. Increased seeding is accompanied by decreased microglial clustering around newly seeded plaques and reduced plaque-associated apolipoprotein E (ApoE). Reduced ApoE deposition in plaques is also observed in brains of AD patients carrying TREM2 coding variants. Proteomic analyses and microglia depletion experiments revealed microglia as one origin of plaque-associated ApoE. Longitudinal amyloid small animal positron emission tomography demonstrates accelerated amyloidogenesis in Trem2 lossof-function mutants at early stages, which progressed at a lower rate with aging. These findings suggest that in the absence of functional Trem2, early amyloidogenesis is accelerated due to reduced phagocytic clearance of amyloid seeds despite reduced plaque-associated ApoE.
I n many neurodegenerative disorders, misfolded amyloidogenic proteins propagate and spread throughout the brain in a characteristic manner reminiscent of prion-like disorders 1 . Seeding and spreading can be experimentally induced by intracerebral injection of homogenates derived from brains of humans with neurodegenerative disorders or respective mouse models 2 . Although little is known about the cellular mechanisms controlling and modifying prion-like propagation, it is conceivable that amyloid-β peptide (Aβ ) clearance may be involved. Microgliosis has long been known as an overarching pathological phenomenon that is characteristic of almost all neurodegenerative disorders 3 . The recent identification of coding variants in genes that are selectively expressed in microglial cells and their genetic association with late-onset Alzheimer's disease (AD) and other neurodegenerative disorders, further pinpoint a pivotal disease-modifying role of microglia 4, 5 . Among these microglial-expressed disease-associated genes, sequence variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an extraordinarily increased risk for AD comparable to that conferred by the single apolipoprotein E (APOE) ε 4 allele 6, 7 . Trem2 is functionally required for a wide variety of important cellular functions, including chemotaxis 8 , maintenance of energy metabolism 9,10 , engulfment of dead cells 8 and phagocytosis of Aβ fibrils 11 . Recent findings have indicated that microglia switch from a homeostatic state to a neurodegenerative phenotype in several different disease models by suppressing their homeostatic messenger RNA profile and increasing a disease-associated transcriptional profile [12] [13] [14] . Trem2 and ApoE are both robustly upregulated in microglia responding to brain lesions 13, 14 . Moreover, ApoE is a major constituent of amyloid plaques and ApoE promotes their aggregation and deposition [15] [16] [17] . Furthermore, anti-ApoE immunotherapy inhibits amyloid accumulation and deposition further supporting the role of ApoE in Aβ aggregation and clearance 18 . Conflicting data on the potential role of Trem2 in amyloid metabolism have been explained by the different model systems used, the show increased amyloid seeding in the dentate gyrus at 4 months when injected with APPPS1 brain homogenates. Insets show seeding pathology at higher magnification as indicated by the area in dotted white box. c,d, Mice were analyzed for 4G8-positive immunoreactivity (n +/+ = 8 mice, n −/− = 7 mice, n p.T66M = 7 mice; F 2,19 = 13.13, P = 0.0003) (c) and ThioS-positive Aβ deposits (n +/+ = 7 mice, n −/− = 6 mice, n p.T66M = 6 mice; F 2,16 = 16.73, P = 0.0001) (d). e, Aβ 42 levels quantified in formic acid fractions using Meso Scale Discovery electrochemiluminescence assay confirm increased amyloid seeding in APPPS1/Trem2 −/− and APPPS1/Trem2 p.T66M mice compared with APPPS1/Trem2 +/+ mice (n = 8 mice/genotype; F 2,21 = 9.016, P = 0.0015). f, Immunoblotting with the anti-Aβ antibody 6E10 demonstrates increased Aβ in the formic acid fraction of APPPS1/Trem2 −/− and APPPS1/Trem2 p.T66M compared with APPPS1/Trem2 +/+ mice. Western blots were independently repeated five times to analyze n = 10 mice/genotype. Full image of immunoblots are shown in Supplementary Fig. 7 . Data represent mean ± s.e.m. One-way ANOVA, Dunnetts's post hoc analysis; *P < 0.05, **P < 0.005, ***P < 0.0005. stage of neuropathology, and the artificially increased production and rapid deposition of Aβ in transgenic mouse models highly overexpressing the amyloid precursor protein (APP) along with autosomal dominant APP and presenilin (PSEN) mutations 5, [19] [20] [21] [22] .
To elucidate the role of Trem2 at the earliest accessible time point in the amyloid cascade, we used an in vivo seeding paradigm and performed intrahippocampal injections of Aβ -containing brain extracts into APPPS1 transgenic mice that previously have been random distribution of IBA1-positive microglia in C57BL6 mice. Second row: clustering of IBA1 and Trem2-positive microglia around seeded plaques in the hippocampus of APPPS1/Trem2 +/+ mice. Third and fourth rows: loss of Trem2 function reduces microglia clustering around seeded plaques. b, IBA1-positive microglia clustering around seeded amyloid plaques (n +/+ = 9 mice, n −/− = 7 mice, n p.T66M = 7 mice, F 2,20 = 38.87, P = 1.5 × 10 -7 ) normalized to seeded amyloid pathology shown in Fig. 1c . c, IBA1 immunoreactivity quantified in the hippocampus excluding seeded dentate gyrus (n +/+ = 10 mice, n −/− = 9 mice, n p.T66M = 9 mice, F 2,25 = 1.657, P = 0.2109). d, First row: CD68 expression is at the detection limit in C57BL6 mice. Second row: increased CD68 staining in IBA1-positive microglia around seeded plaques in the presence of functional Trem2. Third and fourth rows: reduced CD68 expression in microglia around seeded plaques in the absence of functional Trem2. e, Quantification of CD68-positive microglia in the seeded dentate gyrus (n = 6 mice/genotype, F 2,15 = 44.87, P = 4.6 × 10 -7 ) normalized to seeded amyloid pathology shown in Fig. 1a . Dotted white boxes indicate the area in each staining that is merged and shown at higher magnification. Data represent mean ± s.e.m. One-way ANOVA, Dunnett's post hoc analysis; NS, not significant; P > 0.05; ***P < 0.0005.
shown to robustly induce Aβ plaque formation in vivo 2 . By additionally analyzing non-experimentally seeded cortical Aβ plaques, we could directly compare the effect of Trem2 on more mature plaques within the same mice. Furthermore, we used longitudinal small animal positron emission tomography (μ PET) imaging to monitor microglial activation and the kinetics of amyloid deposition up to an age of 12 months. Finally, we investigated microglial clustering and ApoE deposition in amyloid plaques in loss-of-Trem2-function mice as well as in AD cases with TREM2 coding variants.
Results
Increased amyloid plaque seeding in the absence of functional Trem2. Amyloid plaques can be induced experimentally in vivo by a prion-like mechanism via inoculation of Aβ -containing homogenates in transgenic mice. Intracerebral injection of Aβ -rich brain extracts from AD patients or from aged APP transgenic mice promotes early formation and seeding of plaques 2, 23 . Compared with non-experimentally seeded APP transgenic mice, the seeding model provides the unique opportunity to study plaque formation within a very defined and early time window with minimal variation from one mouse to another 2, 23 . In contrast, uninjected non-seeded APP mice do not develop any seeded plaques and have an unpredictable onset of plaque formation at young age. Therefore, to examine the very early effects of loss of Trem2 function on the premature formation of Aβ plaques as well as on the capacity of microglia to remove Aβ seeds, we stereotactically injected brain homogenates derived from APP transgenic mice expressing APP 695KM670/671NL and PSEN1 L166P (APPPS1 mice) 24 into hippocampi of six-week-old APPPS1/Trem2 +/+ , APPPS1/Trem2 -/-(ref. 25 ), or APPPS1/Trem2 p.T66M (ref. 10 ) mice as well as non-transgenic C57BL6 littermates ( Fig. 1a and Supplementary Fig. 1a ). Ten weeks later, at a time point when normally little to no plaques are observed within the hippocampus ( Supplementary Fig. 1a ,b) 2 , mice were killed and brains were prepared for immunohistochemistry and protein analysis. No seeded plaques were observed within the hippocampi of non-transgenic C57BL6 mice ( Supplementary Fig. 1a ,b), two weeks post-injection controls ( Supplementary Fig. 1c ), or uninjected APPPS1/Trem2 +/+ , APPPS1/Trem2 -/-, or APPPS1/Trem2 p.T66M mice ( Supplementary  Fig. 1d ). In contrast, intense amyloid plaque seeding was observed in the subgranular layer of the hippocampi of APPPS1/Trem2 +/+ mice on injection of Aβ -containing brain homogenates as previously published 2,23 ( Fig. 1b and Supplementary Fig. 1a,b ). No seeding was observed on injection of lysates from Aβ -free C57BL6 mice ( Supplementary Fig. 1a ,b). As previously described by Meyer-Luehmann et al. 2 , seeded amyloid plaques had a coarse and punctate appearance ( Fig. 1b and Supplementary Fig. 1a ) in the presence of Trem2. In contrast, in the absence of Trem2, the area occupied by seeded amyloid plaques not only increased ( Fig. 1b ), but also showed a more diffuse 4G8 staining as well as less separation of individual thioflavine S (ThioS)-positive fibrillar Aβ puncta ( Fig. 1b ). While all seeded amyloid plaques were detected immunopositively by 4G8 antibody, ThioS stained the dense cored plaques only. Although the T66M mutation has been strongly linked to Nasu-Hakola disease and frontotemporal dementia-like syndrome rather than AD 26 , we used the APPPS1/Trem2 p.T66M model to investigate Trem2-dependent microglial effects on amyloid seeding in a second independent loss-of-function model 10, 11 . Similar findings were obtained when we injected Aβ -containing brain homogenates in hippocampi of APPPS1 mice endogenously expressing the Trem2 p.T66M loss-of-function mutation (APPPS1/Trem2 p.T66M ) 10 (Fig. 1b) . Quantitative image analysis, Aβ 42 enzyme-linked immunosorbent assay (ELISA), as well as western blotting confirmed increased amyloidogenesis in the absence of functional Trem2 ( Fig. 1c-f ). These findings show that Trem2-dependent microglial functions limit early amyloidogenesis.
Reduced microglial clustering around seeded plaques in the absence of functional Trem2. Since chemotaxis and plaque association of microglia is disturbed on loss of Trem2 function 8, 20, 27 , we next investigated clustering of microglia around newly seeded plaques. In C57BL6 control mice injected with APPPS1 mouse brain homogenate, microglia were randomly distributed throughout the hippocampus and microglial Trem2 expression was below the detection limit ( Fig. 2a ). In contrast, microglia clustered around seeded plaques on injection of Aβ -containing brain homogenates into APPPS1/Trem2 +/+ mice and increased Trem2 expression ( Fig. 2a ). Moreover, microglia clustering was severely reduced in APPPS1/ Trem2 -/or APPPS1/Trem2 p.T66M mice ( Fig. 2a,b ), although the density of ionized calcium-binding adaptor molecule 1 (IBA1)-positive microglia outside the seeded plaque-laden dentate gyrus was not significantly different ( Fig. 2c ). Clustering of microglia around seeded plaques was accompanied by increased CD68 staining, a marker for lysosomal activity, which was significantly reduced in APPPS1/ Trem2 -/or APPPS1/Trem2 p.T66M mice ( Fig. 2d,e ). Contrary to Trem2 loss-of-function mice, intracellular 6E10-positive Aβ staining was observed in plaque-associated IBA1, Trem2, and CD68positive microglia in APPPS1/Trem2 +/+ mice, indicating microglial engulfment and phagocytosis of amyloid plaques ( Fig. 2a,d ).
In line with previous data 9, 19, 20 , microglia also clustered around non-experimentally seeded cortical Aβ plaques ( Supplementary  Fig. 2a,b ), and exhibited a robust increase of Trem2 ( Supplementary  Fig. 2a ) and CD68 expression ( Supplementary Fig. 2c ). Again, Fig. 3 | increased amyloidogenesis in young Trem2 deficient mice is followed by lower amyloid accumulation rates during aging. a, Cortical microglial activity measured by in vivo TSPO μ PET at ages of 3 (P = 0.418), 6 (P = 0.426), and 12 months (P = 0.002) for Trem2-deficient APPPS1 mice compared with APPPS1/Trem2 +/+ . Age-matched results for C57BL6 mice with and without Trem2 deficiency are implemented for comparison with mice lacking amyloid pathology. b, Corresponding results for cortical fibrillar amyloidogensis assessed by in vivo amyloid μ PET at 3 (P = 0.026), 6 (P = 0.007), and 12 months (P = 0.895). (APPPS1: 3 months Aβ PET n +/+ = 4 mice, TSPO PET n +/+ = 5 mice, Aβ PET n −/− = 7 mice, TSPO PET n −/− = 9 mice; 6 months Aβ PET n +/+ = 12 mice, TSPO PET n +/+ = 13 mice, Aβ PET n −/− = 9 mice, TSPO PET n −/− = 11 mice; 12 months Aβ PET n +/+ = 11 mice, TSPO PET n +/+ = 11 mice, Aβ PET n −/− = 7 mice, TSPO PET n −/− = 7 mice. C57BL6: 3 months Aβ PET n +/+ = 6 mice, TSPO PET n +/+ = 6 mice, Aβ PET n −/− = 5 mice, TSPO PET n −/− = 6 mice; 6 months Aβ PET n +/+ = 25 mice, TSPO PET n +/+ = 20 mice, Aβ PET n −/− = 6 mice, TSPO PET n −/− = 8 mice; 12 months Aβ PET n +/+ = 21 mice, TSPO PET n +/+ = 20 mice, Aβ PET n −/− = 7 mice, TSPO PET n −/-= 7 mice). SUVR WM , standardized uptake value ratio to white matter. Error bars represent mean ± s.d. Two-sided t test. c, Coronal and axial slices show Z-scores of increased TSPO μ PET against age-matched C57BL6 (n = 18 mice) to compare APPPS1/ Trem2 −/− and APPPS1/Trem2 +/+ at 3, 6, and 12 months of age using an MRI template. d, Coronal and axial slices show Z-scores of increased amyloid μ PET against age-matched C57BL6 (n = 18 mice) to compare APPPS1/Trem2 −/− and APPPS1/Trem2 +/+ at 3, 6, and 12 months. e, Serial imaging shows distinctly lower monthly increases for TSPO μ PET during aging (6-12 months) in APPPS1/Trem2 −/− mice compared with APPPS1/Trem2 +/+ mice (n +/+ = 11 mice, n −/− = 11 mice, 3-5 months P = 0.756, 6-8 months P = 8.03 × 10 -7 , 9-11 months P = 0.003). f, Serial amyloid μ PET indicates an increased accumulation rate of fibrillar amyloidogenesis in young APPPS1/Trem2 −/− mice (3-5 months) compared with age-matched APPPS1/Trem2 +/+ mice. Notably, the accumulation rate of fibrillar amyloid in APPPS1/Trem2 −/− mice declines below those of APPPS1/Trem2 +/+ during aging (6-12 months) n +/+ = 10 mice, n −/− = 9 mice, 3-5 months P = 1.52 × 10 -4 , 6-8 months P = 0.003, 9-11 months P = 1.48 × 10 -4 ). Thick lines in e and f represent polynomic functions of longitudinal changes, whereas dotted lines represent functions of s.e.m. Two-sided t test. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001.
clustering of microglia as well as CD68 expression were both reduced in Trem2 loss-of-function mice ( Supplementary Fig. 2a-d ), whereas the density of IBA1-positive microglia in a non-plaque bearing area such as the thalamic nuclei was not significantly different ( Supplementary Fig. 2e ).
Loss of Trem2 function changes the kinetics of amyloidogenesis.
Conventional immunohistochemical analyses of brain-region-specific amyloid plaque burden in Trem2-deficient APP transgenic mice at different ages have yielded conflicting results 5, [19] [20] [21] [22] . Therefore, to longitudinally investigate whether amyloid plaque accumulation is affected by Trem2 loss of function during disease development in the entire brain, we performed dual-tracer longitudinal µ PET imaging using tracers for amyloidogenesis (florbetaben) and microglia activation (translocator protein; TSPO) 28 ( Fig. 3 and Supplementary Fig. 3 ). APPPS1 as well as C57BL6 mice with and Supplementary  Fig. 3a-d ). However, due to limited resolution, µ PET was not appropriate for in vivo assessment of small hippocampal plaques in the seeding model. Additionally, individual µ PET data of each imaging time point were validated by corresponding immunohistochemistry, which gave strong correlations between X-34 staining and the amyloid µ PET signal as well as between CD68 staining and the TSPO µ PET signal ( Supplementary Fig. 3e -l). Supplementary Fig. 7 . b, ApoE LFQ intensities of microglia-enriched lysates in APPPS1/Trem2 +/+ mice compared with age-matched C57BL6 controls. Two-sided Student's t test comparing log 2 -transformed LFQ intensities of APPPS1 (n = 3 mice) and C57BL6 (n = 3 mice) separately for 3 (P = 0.061), 6 (P = 0.00372), and 12 months (P = 1.78 × 10 -5 ) of age (**P < 0.01; ***P < 0.001). c, ApoE LFQ intensities of microglia-enriched lysates from 12-month-old APPPS1/Trem2 −/− mice show significantly reduced ApoE compared with age-matched APPPS1/Trem2 −/− controls (n = 3 mice/genotype). APPPS1 mice show significant reduction in ApoE after loss of Trem2 (P = 0.00105). d, ApoE and IBA1 co-stained in 12-month-old APPPS1/Trem2 +/+ and APPPS1/ Trem2 −/− mice. White boxes indicate the area in each staining that is magnified as inset. e, Microglia-depleted lysates from 12-month-old APPPS1 mice show no statistically significant changes regardless of Trem2 expression (n = 3 mice/genotype; P = 0.979). Data represent mean ± s.d. f, ApoE and GFAP co-stained in 12-month-old APPPS1/Trem2 +/+ and APPPS1/Trem2 −/− mice. White boxes indicate the area in each staining that is magnified as inset. As expected, microglial activation was highly increased in APPPS1/Trem2 +/+ mice at 12 months compared with age-matched C57BL6 mice without amyloidogenesis (Fig. 3a,c) . Trem2 lossof-function APPPS1 mice mainly displayed a reduced ability of microglial activation at 12 months of age when compared with agematched APPPS1/Trem2 +/+ (Fig. 3a,c) . Importantly, we observed a significantly reduced longitudinal progression of microglial activity ( Fig. 3e and Supplementary Fig. 3a ,c) from 3 to 12 months of age in APPPS1/Trem2 −/− compared with APPPS1/Trem2 +/+ mice. Increased microglial activation in APPPS1/Trem2 +/+ compared with APPPS1/Trem2 −/− or C57BL6 mice reflected the previously observed high 18 [F]-GE180 uptake in microglial cells and low retention in the non-inflamed and non-diseased brain 29 .
Interestingly, amyloid μ PET imaging revealed an increased fibrillar amyloidogenesis early during pathogenesis in APPPS1/Trem2 −/− mice at 3 and 6 months, which leveled out during late disease progression at 12 months of age ( Fig. 3b,d) . Noteworthy, fibrillar amyloidogenesis was already significantly elevated in 3-month-old APPPS1/Trem2 −/− compared with age-matched APPPS1/Trem2 +/+ mice. Furthermore, we observed a significantly lower accumulation rate of fibrillar amyloid from 6 to 12 months of age ( Fig. 3f and Supplementary Fig. 3b,d) . In contrast, monthly rates of fibrillar amyloid accumulation were elevated in APPPS1/Trem2 −/− compared with APPPS1/Trem2 +/+ mice between 3 and 6 months of age ( Fig. 3f ). This suggests an initial phase of enhanced fibrillar amyloidogenesis is followed by a later phase of slower amyloid deposition or alternatively, an earlier saturation of amyloid deposition in Trem2 knockout mice as a result of an elevated baseline. Regardless of the mechanism involved, this may suggest that additional agedependent factors contribute to plaque growth and clearance during disease progression.
ApoE load of amyloid plaques depends on functional Trem2.
Since disease-associated microglia migrate toward amyloid plaques and increase ApoE mRNA 13, 14, 30 , we wondered whether ApoEexpressing microglia might directly contribute to the ApoE load of amyloid deposits and therefore could contribute to the observed changes in the kinetics of amyloid plaque deposition. To find out whether microglia or astrocytes and other neuronal cells selectively contribute to the entire pool of ApoE, we first compared ApoE protein abundance in lysates from microglia-enriched and microgliadepleted fractions obtained from 12-month-old APPPS1 mice in the presence or absence of Trem2. Enrichment of microglia as well as depletion of microglia was confirmed in the corresponding fractions by western blotting with antibodies to microglial, astroglial, neuronal, and oligodendrocytic marker proteins (Fig. 4a ). Protein abundance of ApoE in microglia-enriched fractions increased from 3 to 12 months in APPPS1/Trem2 +/+ mice (Fig. 4b ). Moreover, proteomic analysis of APPPS1/Trem2 +/+ mice revealed increased ApoE abundance selectively in the microglia-enriched fraction when compared with APPPS1/Trem2 −/− mice ( Fig. 4c ). Increased production of ApoE in microglia was further confirmed by ApoE/ IBA1 co-stainings ( Fig. 4d ). In contrast, the microglia-depleted fraction showed no Trem2-dependent change in ApoE production ( Fig. 4e ), which was also confirmed by immunohistochemistry ( Fig. 4f ). This suggests that microglia may be directly involved in the process of ApoE co-deposition in amyloid plaques, since the strong increase of microglial ApoE expression occurs only when microglia switch to the disease-associated signature on clustering around amyloid plaques 13, 14 . We therefore investigated deposition of ApoE in newly seeded amyloid plaques in the presence and absence of Trem2-dependent microglial clustering. Seeded plaques within the hippocampus were robustly co-stained with ApoE in APPPS1/ Trem2 +/+ mice (Fig. 5a ). In contrast, on loss of Trem2 function, newly seeded hippocampal plaques showed a significant reduction of plaque-associated ApoE (Fig. 5b-d ) despite higher plaque load. Reduced plaque-associated ApoE was confirmed by western blotting of plaque-enriched formic acid hippocampal extracts (Fig. 5e ). Similar findings were obtained when we investigated non-experimentally seeded cortical Aβ plaques in the same mice ( Fig. 6 ). Again, while APPPS1/Trem2 +/+ mice showed robust ApoE association with amyloid plaques (Fig. 6a ), the ApoE load in cortical plaques of APPPS1/Trem2 -/or APPPS1/Trem2 p.T66M mice was significantly reduced ( Fig. 6b-e ). Similarly, co-immunostaining of ApoE and IBA1-positive microglia was significantly lower on loss of Trem2 function compared with APPPS1/Trem2 +/+ mice (Fig. 6f ). This is in line with both the absence of ApoE mRNA induction in microglia on loss of Trem2 function 8, 14 , and the age-dependent increase in ApoE protein levels in microglia from APPPS1/Trem2 +/+ mice (Fig. 4b) . Indeed, in APPPS1/Trem2 +/+ mice, microglia clustering around seeded plaques within the hippocampus (Fig. 5a ) or around non-experimentally seeded cortical Aβ plaques (Fig. 6a ) express enhanced levels of ApoE in contrast to microglia in Trem2 loss-of-function mice as shown by three-dimensional (3D) reconstruction of high-resolution confocal images (Figs. 5b-e and 6b-f). Thus, loss of Trem2 function leads to a rather dramatic reduction of ApoE co-deposition in amyloid plaques.
To independently verify microglia as one source of amyloid plaque-associated ApoE, we investigated ApoE co-deposition in amyloid plaques in brains of microglia-depleted APPPS1 mice ( Fig. 7) . APPPS1 mice crossed to mice expressing thymidine kinase of herpes simplex virus (TK) under the CD11b promoter were used for this study 31 . TK as a suicide gene converts antiviral nucleotide analog prodrugs such as ganciclovir (GCV) into a monophoshorylated form, which is subsequently transformed into a toxic triphosphate variant by cellular kinases. GCV treatment for longer than three weeks can lead to microhemorrhages in the brain as well as increased rate of lethality 31 . With these limitations in mind, we decided to include 3-month-old APPPS1/TK+ mice treated with GCV for two weeks only to avoid side effects (Fig. 7a) . Moreover, the subsequent two weeks during which no GCV was administered allowed repopulation of the brain parenchyma with peripheral monocytes, which failed to cluster around plaques 32 . Compared with APPPS1/TK-controls, immunohistochemical analyses demonstrated significantly reduced plaque-associated ApoE on microglial depletion (Fig. 7b-f and Supplementary Fig. 4a ).
Moreover, newly re-populated IBA1-positive cells in APPPS1/TK+ mice displayed decreased IBA1/ApoE co-staining (Fig. 7d,g and Supplementary Fig. 4b) . In contrast to microglia, glial fibrillary acidic protein (GFAP)-positive astrocytic staining in both APPPS1/ TK mice showed no changes in GFAP/ApoE co-localization ( Fig. 7e,g and Supplementary Fig. 4c ). These findings provide further evidence for the pivotal role of microglia as one source of plaque-associated ApoE. Reduced ApoE in amyloid plaques of AD patients with TREM2 variants. To test whether these preclinical findings have relevance for humans, we analyzed ApoE co-deposition in amyloid plaques in brains from AD patients with and without TREM2 variants ( Fig. 8 and Supplementary Fig. 5 ). Reduced ApoE colocalization with amyloid plaques was also observed in AD patients with the TREM2 p.R47H, p.R62C, p.R62H, and p.D87N loss-of-function variants when compared with AD cases without TREM2 variants (Fig. 8a-c and Supplementary Fig. 5a-c) . ApoE reduction was most pronounced in cases with TREM2 variants at amino acid 62, a position where an amino acid change has been confirmed to result in an increased risk for developing late-onset AD 33 . Reduced ApoE in amyloid plaques was further confirmed by western blotting of plaque-enriched formic acid extracts from brains with TREM2 variants compared with those without TREM2 coding variants, which was significant on normalization to Aβ 42 concentration (Fig. 8e,f and Supplementary Fig. 5f ). Based on the findings in mouse brains (Fig. 2a,b and Supplementary Fig. 2 ), we expected that microglia in brains of TREM2 mutation carriers should have a reduced capacity to cluster around amyloid plaques. Indeed large clusters of microglia around amyloid plaques were frequently found in AD cases without TREM2 variants but were far less frequently detected in AD patients with TREM2 loss-of-function variants (Fig. 8d,g and Supplementary Fig. 5d,g) . While there was a trend in increased plaque-associated Aβ 42 with the number of E4 isoforms present, an ApoE genotype specific effect was not observed on plaque-associated microglia ( Supplementary Fig. 5h,i) . These data demonstrate that several independent TREM2 coding variants all cause a loss of function of TREM2 resulting in reduced microglial clustering and ApoE accumulation in amyloid plaques.
Discussion
Our findings indicate that TREM2-dependent microglial functions limit amyloid plaque growth early but not late during the disease. For lowering amyloidogenesis, a TREM2-dependent activity is required that allows clustering of microglia around newly seeded amyloid plaques. In the presence of functional Trem2, phagocytic CD68-positive microglia accumulate around amyloid plaques and may initially promote Aβ clearance. Meanwhile, microglia that cluster around amyloid plaques increase ApoE expression 12, 13, 30 and may generate a microenvironment, which could lead to an increased ApoE concentration in the immediate neighborhood of Aβ deposits ( Supplementary Fig. 6 ). In line with the well-described function of ApoE in amyloidogenesis [15] [16] [17] , this may further promote Aβ aggregation and deposition. Consequently, high levels of ApoE in amyloid plaques may support their fibrillization and compaction, which is reflected by the longitudinal amyloid µ PET imaging data. This is further supported by the recent finding that ApoE-deficient mice as well as mice expressing the AD-associated p.R47H TREM2 variant exhibit a striking reduction of plaque compaction 34, 35 . In the absence of functional Trem2, microglia activation is dramatically reduced as shown by longitudinal TSPO µ PET imaging. While using TSPO radiotracers to study neuroinflammation may present certain limitations, such as the presence of non-binders and unspecific binding to multiple types of immune cells including astrocytes 36 , the high affinity for TSPO with better brain uptake, retention, clearance, and improved signal-to-noise ratio makes the enantiomerically stable tricyclic compound [ 18 F]-GE180 a suitable agent for imaging neuroinflammation in vivo [37] [38] [39] . Furthermore, the specificity of microglial activation has also been confirmed by in vitro autoradiography and immunohistochemistry using different transgenic models with varying degrees of neuroinflammation 10, 28, 40, 41 . Nonetheless, future development of radioligands should facilitate in vivo detection of even more specific phenotypes of microglia activation. Microglia clustering is abolished in Trem2 loss-of-function mice leading to reduced phagocytic amyloid plaque clearance but also to significantly less ApoE accumulation in amyloid plaques (both, in seeded and non-experimentally seeded cortical Aβ plaques; Supplementary Fig. 6 ). Reduced ApoE accumulation is in line with the finding that microglia lacking functional Trem2 suppress the disease-associated mRNA signature and appear to be locked in a homeostatic state with repressed ApoE expression 8, [12] [13] [14] 30 . Thus, absence of ApoE-expressing microglia in the immediate neighborhood of amyloid plaques may result in reduced ApoE co-aggregation in amyloid plaques ( Supplementary Fig. 6 ), which is further supported by our finding that microglia depletion leads to a rather dramatic decline of plaque-associated ApoE. This also demonstrates that Trem2-dependent microglial uptake of ApoE 42 could not be the sole reason for increased ApoE in microglia, since on microglia depletion amyloid plaques should then contain higher and not lower ApoE levels. Thus, microglia may be one source of plaqueassociated ApoE although an additional contribution of astrocytes cannot be excluded. For example, microglia may signal to astrocytes in a TREM2-dependent manner and may thus influence astroglial release of ApoE. Furthermore, the ApoE antibodies used may preferentially recognize a microglial ApoE variant. Future studies using ApoE antibodies that selectively recognize lipidated versus unlipidated ApoE could provide additional insights into potential mechanisms underlying our observations. ApoE is predominantly synthesized in and secreted by astrocytes in non-diseased mouse 43 and human brain 44 . However, our study demonstrates that ApoE protein levels are strongly induced in plaque-associated microglia under disease conditions in a Trem2dependent manner. This is in contrast to Trem2 loss-of-function microglia that are locked in a homeostatic state 8, 14 . A limitation of our study is the use of murine Trem2 and Apoe for investigating the interaction between microglia and amyloid pathology. Future studies should include humanized TREM2 and APOE variants as these may influence Aβ metabolism and therefore amyloid pathogenesis 45 . With these limitations in mind, we studied the effect of TREM2 coding variants in the AD patients. The observed reductions in plaque-associated microglia and ApoE in AD cases with TREM2 White box indicates the area that is magnified for each immunostaining and placed adjacently. d,e, 3D reconstructed images of X-34/IBA1/ApoE/GFAP quadruple immunostaining in APPPS1/TKand APPPS1/TK + mice. Channels from the same confocal image were split to focus on co-staining with IBA1 or GFAP individually. d, Left: X-34/ApoE/IBA1 co-staining shows increased IBA1 and ApoE colocalization with amyloid plaques in APPPS1/TKmice compared with APPPS1/ TK + mice (right). Smaller images placed adjacently display each channel separately and merged channels (indicated by white box). e, X-34/ApoE/GFAP immunostaining demonstrates no qualitative differences in APPPS1/TKmice (left) compared with APPPS1/TK + mice (right). White box indicates the area that is magnified for each immunostaining and placed adjacently. f, Plaque-associated ApoE staining quantified from immunostainings shown in b and c (n = 3 mice/genotype, P = 0.0034). g, Quantification of percentage IBA1/ApoE (n = 3 mice per genotype, P = 0.0004) and GFAP/ApoE colocalization (n = 3 mice/genotype, P = 0.4464) from stainings displayed in d and e, respectively. Data represent mean ± s.d. Two-tailed unpaired t test with Welch's correction; NS, P > 0.05; **P < 0.005; ***P < 0.001. coding variants further support our findings and raise the possibility that microglial ApoE is induced in a TREM2-dependent manner in humans as well. To finally address this question, it will be important to study human microglial cells by single-cell sequencing.
Although we cannot fully exclude a saturation of amyloid plaque pathology late during disease progression in the Trem2 loss-of-function mutants, it is tempting to speculate that early reduced plaque clearance in the absence of functional Trem2 may be opposed by less ApoE-driven amyloidogenesis later during disease progression. This could explain why late in the disease, levels of amyloid deposition converge in the presence and absence of functional Trem2. The age-dependent change in biphasic rate of amyloidogenesis observed in the absence of functional Trem2 is also consistent with the disease progression-dependent effects of Trem2 deficiency on Fig. 8 | Reduced ApoE levels in Aβ plaques and impaired microglial clustering in TREM2 coding variants. a, Temporal neocortex of human AD patients with and without the indicated TREM2 variants stained for Aβ by 4G8 immunohistochemistry. b, In sections consecutive to those of the left column, AD patients with TREM2 variants show reduced ApoE immunoreactivity within amyloid plaques compared with an AD case with no TREM2 coding variants (no CV). Note that the ApoE reduction is most pronounced in cases with an amino acid exchange at position 62. Red boxes indicate the area in each staining that is magnified as inset. c, More examples of ApoE stainings comparing the same region in consecutive Aβ stained sections. d, IBA1 (brown) and 4G8 (red) co-staining in temporal neocortex. Microglia cells association with amyloid plaques as seen in a no-CV case (last row) is severely impaired in AD cases with different TREM2 coding variants (rows 1-4). Furthermore, the overall density of microglial cells is reduced in TREM2 variant AD cases when compared with no CV. Dotted black boxes indicate the area magnified as inset. e, ApoE immunoblotted in plaque-enriched formic acid fractions from cases shown in a-d and additional cases shown in Supplementary Fig. 5 . Full image of the immunoblot is shown in Supplementary Fig. 7 . f, ApoE/Aβ 42 ratio quantified from plaque-enriched formic acid fraction shows significantly decreased ApoE levels in AD cases with TREM2 coding variants (n R47H = 2 cases, n R62H = 4 cases; n R62C = 1 case) compared with no CV (n = 4 cases; P = 0.0121). Of note, frozen material from p.D87N cases was not available and therefore not included. One of the no-CV cases was excluded due to diagnosed hepatitis. g, Number of IBA1-positive microglia per plaque quantified from images shown in d and Supplementary Fig. 5d (n R47H = 2 cases, n R62H = 4 cases; n R62C = 1 case; n D87N = 2 cases; n no CV = 3 cases; P = 3.9 × 10 -4 ). Noteworthy, sections from only three no CV cases were available in comparison to frozen material. No subjects were excluded in this analysis. Medial temporal cortex at the level of anterior hippocampus was used for all experiments. Data represent as mean ± s.d. Unpaired two-tailed t test with Welch's correction; *P < 0.05; ***P < 0.001. amyloid plaque deposition at late time points reported by Jay et al. 19 . However, at very early time points we observe differences in baseline levels of fibrillar amyloid pathology, which could be explained by slightly different ages, the use of different technologies, as well as regions of interest used to follow amyloidogenesis. In this regard, it needs to be considered that 18 F-florbetaben has a strong affinity to dense fibrillar amyloid plaques compared with diffuse amyloid deposition.
TREM2-dependent effects on ApoE load of amyloid plaques must be considered for any attempt to therapeutically modulate TREM2 and microglial function in general. Since we observe enhanced amyloidogenesis of TREM2 mutants only at early stages of the disease, and since these differences may be compensated later by the reduced microglial production of ApoE, our findings support the observation that the disease is manifested decades before clinical symptoms occur 46 . AD-associated TREM2 loss-of-function variants may thus promote seeding selectively at an early phase of the disease. Seeded plaques have been reported to be neurotoxic by decreasing neurogenesis and increasing neuronal cell death in their immediate neighborhood 47 . Thus by eliminating newly seeded plaques, TREM2 may have protective functions at least early during amyloidogenesis. A protective function of TREM2 is also supported by the finding that disease-associated TREM2 variants cause a loss of function (for example, refs. 10, 11, 42, 48 ). This is consistent with the finding of increased soluble TREM2 in cerebrospinal fluids of patients of the Dominantly Inherited Alzheimer Network (DIAN) cohort already five years before onset of clinical symptoms, which may reflect a defensive microglial activation at an early state of the disease 49 . However, microglia not only modulate amyloid plaque clearance but also provide ApoE as an Aβ aggregation factor 17 , which could consequently facilitate amyloidogenesis. Finally, our finding that microglia influence amyloid plaque fibrillarity depending on their activation state is highly relevant for clinical studies as longitudinal amyloid PET is a read-out for amyloid-based therapies 50 .
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Methods
Transgenic mice. All animal experiments were approved by the Bavarian government and performed in accordance with local animal handling laws. Fourmonth-old male APPPS1 transgenic mice (Thy1-APP 695KM670/671NL ; Thy-1PS1 L166P ) 24 and age-matched male C57BL6 littermate controls were used. Using male mice ensured reduced gender-dependent variability in plaque deposition 24 .
APPPS1 mice were crossed to Trem2 -/mice 25 and maintained on a C57BL6J background. Additionally, APPPS1 were crossed to achieve homozygous Trem2 p.T66M knock-in mice 10 , which were maintained on a mixed genetic background (N1 backcross to C57BL6N). The Trem2 p.T66M mice were compared with APPPS1/Trem2 +/+ mice from the same background for all experiments. No differences were observed between wild-type control mice from the Trem2 -/or Trem2 p.T66M mouse lines. For μ PET experiments, 3-, 6-, and 12-month-old female APPPS1/Trem2 +/+ and age-matched APPPS1/Trem2 -/were used. As additional controls, non-transgenic age-matched female C57BL7/Trem2 +/+ as well as C57BL6/Trem2 -/were included.
Randomization and blinding.
For all animal experiments, mice were allocated randomly after genotyping. Mice of different genotype were allocated randomly to PET experiments with scan number and slot, as well as with blinded identity to the experimenter using a chipping system. Investigator was not blinded during the intrahippocampal injection experiments. All the immunohistochemical analysis was initially performed blinded; however, due the strong microglial-clustering impairment phenotype of mice with loss of Trem2 function, complete blinding was not possible. Slides were imaged and saved with random numbers to identify them. Images were then quantified and unblinded to perform group statistics. No statistical methods were used to pre-determine sample sizes but our sample sizes were based on previous findings 2, 10, 28, 31 .
Preparation of brain homogenate for intracerebral injections. Brain homogenates for injection were prepared as previously described 2 . Mouse brain extracts were prepared by dissecting the neocortex of 15-month-old female APPPS1 transgenic mice and age-matched non-transgenic C57BL6 controls. Tissue samples were homogenized at 10% (w/v) in sterile PBS, vortexed, sonicated 3 × 5 s (Bandelin Sonorex RK100H), and centrifuged at 3,000 × g for 5 min at 4 °C. The supernatant was aliquoted and frozen at − 80 °C until use.
Stereotaxic surgery. Six-week-old asymptomatic host mice were anesthetized with a mixture of medetomidin (0.05 mg −1 kg −1 ), midazolam (5 mg −1 kg −1 ), and fentanyl (0.5 mg −1 kg −1 ). As previously described 2 , a 0.5-1.0-cm-long incision was made in the shaved and sterilized skin to expose the bregma. Bilateral stereotaxic injections of mouse brain homogenate (1.25 µ l min −1 over 2 min) were performed with a Hamilton syringe into the hippocampi and overlaying cortices at specific stereotaxic coordinates (anterior-posterior − 2.3 mm, medial-lateral + /− 2.0 mm, dorsal-ventral -0.8/− 2.0 mm). The needle was retained for additional 2 min before it was slowly withdrawn. The incision was cleaned with povidone-iodine antiseptic solution and sutured. Following this, mice were brought out of anesthesia using a mixture of atipamezol (2.5 mg −1 kg −1 ), flumazenil (0.5 mg −1 kg −1 ), and naloxone (1.2 mg −1 kg −1 ), returned to clean cages, and monitored until recovery from anesthesia. Mice were weighed and monitored daily for seven days following surgery. Food and water was provided ad libitum.
Immunofluorescence analyses of mouse brains. Brains were removed after transcardial perfusion with PBS and dissected into two hemispheres. The left hemibrain was immersion-fixed for 48 h in 4% paraformaldehyde, followed by cryoprotection in 30% sucrose for 48 h. After freezing, 25 μ m microtome sections were sequentially collected in PBS with 15% glycerol and kept at − 80 °C until further use. For staining, heat-induced sodium citrate antigen retrieval was performed using 25 mM sodium citrate with 0.05% Tween-20 at 95 °C for 30 min. Free-floating sections were incubated in X-34 for 1 h at room temperature in 60% PBS/40% EtOH mix; pH was adjusted with 1 N NaOH 51 . Sections were washed briefly with 60% PBS/40% EtOH before blocking. Primary antibodies ( Supplementary Table 1 ) were added and the sections were kept at 4 °C overnight with slow agitation. For Trem2 staining, sections were incubated at 4 °C for two nights. After applying the appropriate secondary antibodies, tissue sections were stained with ThioS (0.01%) or 4′ ,6-diamidin-2-phenylindol (DAPI, 5 μ g ml -1 ) before mounting sections onto slides (Prolong Gold Antifade reagent, Thermo Fisher Scientific).
Confocal imaging and analyses. Images were acquired using a LSM 710 Confocal microscope (Zeiss) and the ZEN 2011 software package (black edition, Zeiss). Laser and detector settings were maintained constant for the acquisition of each immunostaining. For all analyses, at least three images were taken per brain region and slide using × 20 objective and × 63 oil differential interference contrast objective, respectively, at 2,048 × 2,048 pixel resolution, with z-step size of 2 μ m at 16 μ m thickness. High-resolution stacks imaged by confocal microscopy were 3D reconstructed using IMARIS 8 software.
For quantification of plaque densities, acquired images were imported to Fiji software (ImageJ) and data channels were separated (image/color/split channels).
Gaussian filtering was used to remove noise and intensity distribution for each image was equalized using a rolling ball algorithm, which is implemented as background subtraction plugin in Fiji. For the feasibility of the quantification, all layers from a single image stack were projected on a single slice (stack/Z projection). Next, the plaques were segmented using automatic thresholding methods in Fiji (with 'Moments' thresholding setting for microglial stainings and 'Otsu' for plaques and ApoE). Subsequently, the dentate gyrus was selected manually whereupon the area as well as the cumulative area of the segmented plaques were calculated in the region of interest. Finally, the coverage of segmented plaques over the area of dentate gyrus was calculated, indicating the distribution of segmented plaques in the dentate gyrus. Similar thresholding was used to quantify cortical plaques as well as IBA1, CD68, and ApoE stainings. The number of IBA1 and CD68-positive microglia around plaques were counted in the cortex over the length of layers 3-5 using ImageJ.
In vivo μPET imaging and quantification. All μ PET procedures followed an established standardized protocol for radiochemistry, acquisition, and postprocessing 52, 53 . In brief, 18 F-GE180 TSPO μ PET with an emission window of 60-90 min post injection was used to measure cerebral microglial activity, and 18 F-florbetaben amyloid μ PET with an emission window of 30-60 min post injection was used for assessment of fibrillar cerebral amyloidogenesis. APPPS1/ Trem2 -/and age-matched APPPS1/Trem2 +/+ mice were longitudinally studied from 6 to 12 months of age using dual μ PET. All analyses were performed by PMOD (V3.4, PMOD Technologies). Normalization of injected activity was performed by the previously validated myocardium correction method 54 for TSPO μ PET and by a white matter reference region for amyloid μ PET.
TSPO and amyloid μ PET estimates (absolute values and percentage changes over time) deriving from the same large neocortical target volume of interest (50 mm³) were extracted and compared between the two age and genotype groups by a Student's t-test. In-house scans of C57BL6 mice served for generation of Z-score deviation images for both tracers (Z-score = (average APPPS1/ TREM2 -/--average C57BL6 )/SD C57BL6 ) or (average APPPS1/TREM2 +/+ -average C57BL6 )/SD C57BL6 ). Percentage changes with baseline as starting point were calculated such that the earliest time interval was set as 3-4 months and the latest at 11-12, depicted as 3 and 11 months.
Patient material. Tissue samples of patient autopsy cases were provided by the Neurobiobank Munich, Ludwig-Maximilians-University (LMU) Munich, and Queen Square Brain Bank for Neurological Disorders, University College London (UCL). Detailed clinical characteristics were ascertained from an integrated autopsy database at respective brain banks. Written informed consent for autopsy and analysis of tissue sample data was obtained for all patients, either from the patients themselves or their next of kin. All samples were collected according to the guidelines of the local ethics committee following all ethical regulations. All requirements for written informed consent was waived by the medical ethics committee that approved the study protocol. Information on cases regarding brain bank, clinical diagnosis age at death, post-mortem delay, AD Braak and Braak stage, TREM2 coding variant, and APOE status is given in Supplementary Table  2 . Sample sizes were based on availability of patient material. For all experiments, temporal neocortex was used which included cortex of medial temporal gyrus at the level of anterior hippocampus.
Genotyping of AD cases. To identify TREM2 variant carriers within the Neurobiobank Munich TREM2 exon 2 was amplified from genomic DNA by PCR, purified using ExoSAP-IT (Thermo Fisher Scientific) and sequenced by standard Sanger sequencing (GATC Biotech). Sequences were aligned to the TREM2 reference sequence (UCSC Genome Browser, assembly GRCh38/hg38; chr6:41,158,506-41,163,186) and variants called manually by two investigators using the CLC Main Workbench Software (Qiagen). To identify pathogenic APP, PSEN1, and PSEN2 mutations all cases were additionally sequenced using a TruSeq CustomAmplicon kit on a MiSeq (Illumina) according to the protocol from the manufacturer. Panel sequencing confirmed all TREM2 variants and was also used to determine the APOE genotype.
Immunohistochemistry on human post-mortem brain tissue. Temporal neocortex sections of 5 μ m thickness were cut from paraffin-embedded specimens. For immunohistochemistry, all slides were deparaffinized and rehydrated in a series of xylene and graded ethanol. The sections were subjected to citric acid antigen retrieval (1 M sodium citrate in PBS, pH 6.0) and boiled in a microwave for 20 min. After cooling, endogenous peroxidase activity was quenched using 30% hydrogen peroxide for 20 min. Sections were blocked and incubated with primary antibody ( Supplementary Table 1 ) overnight at 4 °C. Primary antibodies were detected with biotinylated anti-mouse and anti-rabbit immunoglobulin-G secondary antibodies and visualized with avidin-biotin-complex (ABC-Kit, Vector Laboratories) followed by development with diaminobenzidine-HCl (DAB, Vector Laboratories) for 5 min. Lastly, sections were counterstained with haematoxylin. Stainings were performed in serially cut sections to compare the same region of interest through all immunostainings. For IBA1/4G8 co-stainings, mouse alkaline phosphatase (AP)-conjugated and rabbit horseradish peroxidase (HRP)-conjugated secondary antibodies were incubated at room temperature for 1 h. HRP staining was developed using DAB as mentioned above and AP staining was developed using Permanent AP Red Kit for 20 min at room temperature (Zytomed Systems). We controlled for artifacts resulting from long formaldehyde fixation period by comparing different antigen retrieval methods as well as staining freshly fixed frozen tissue. Brightfield images were taken by CellD, Olympus BX50 Soft Imaging System (Olympus). Plaque-associated ApoE in human temporal neocortex was quantified using the ' Analyze Particles' feature in ImageJ. All thresholded ('Otsu') and masked plaques were selected from the regions of interest manager, and used to measure ApoE in the ApoE-stained serial section. Images from similar regions of interest were taken in all samples, including the superior, middle, and inferior temporal gyri using × 4 as well as × 10 objectives for a better overview of the tissue. Amyloid plaques in the subcortical white matter were not analyzed. The number of IBA1-positive microglia per cortical plaque was scored and counted from 6-10 images per slide. A total of 2,461 plaques were analyzed and only IBA1-positive microglia with visibly stained nuclei were counted.
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Data collection
Confocal images were acquired using a LSM 710 Confocal microscope (Zeiss) and the ZEN 2011 software package (black edition, Zeiss). Stacks were 3D reconstructed using IMARIS 8 software.
Data analysis FIJI (ImageJ) was used for all immunohistochemical analyses. Excel 2011 (Microsoft v14.7.7) was used to calculate the averages of each repeated experiment. Graph Pad (Prism v7.0) was used to build graphs and perform statistical analyses presented throughout the manuscript. All PET analyses were performed by PMOD (v3.4, PMOD technologies, Basel, Switzerland). Sequences for genotyping of AD cases were aligned to the TREM2 reference sequence (UCSC genome browser, assembly GRCh38/hg38; chr6: 41, 158, 163, 186) and variants called manually by two investigators using the CLC Main Workbench Software (Qiagen). Mass-spectrometry analysis and label free protein quantification were performed with the Spectronaut software (v11.0.15038.4.29119, Biognosys) and Maxquant (v1.5.5.1).
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